
    
      This is a randomized (the study medication is assigned by chance), double-blind (neither
      physician nor participant knows the identity of the assigned treatment), placebo-controlled
      (an inactive substance that is compared with a medication to test whether the medication has
      a real effect), parallel-group, multicenter study of the effects of canagliflozin and
      phentermine co-administration in non-diabetic overweight or obese participants. The study
      will be conducted for about 33 weeks, approximately 344 participants will be randomly
      assigned in a 1:1:1:1 ratio to one of the four treatment groups: co-administration of
      canagliflozin and phentermine, canagliflozin alone, phentermine alone, or placebo. All
      participants will be also provided with diet and exercise counseling for weight loss
      (standardized non-pharmacological therapy).
    
  